Boehringer Ingelheim Investment in avian vaccines
The German group has laid the first stone of a 5,700 m2 building at its Lyon Porte-des-Alpes (LPA) site. Known as F2IVE (Formulation and Filling of Inactivated Vaccines Extension), this major project will comprise a three-storey building - including 1,000 m2 of clean room space – mainly for formulating and distributing avian vaccines.
The new building, which has an environmentally friendly design, will house two formulation lines, a multi-format bottle distribution line and a bag distribution area.
Earthworks for the new high-tech building began in March 2018 with the first batches expected in spring 2020 for a range of avian vaccines destined for the world market, with the exception of the US.
Fifteen months after the acquisition of Merial (a Sanofi company) in January 2017, this new investment will lead to the creation of 42 new jobs, primarily consisting of qualified operations staff (flow and maintenance managers, production technicians).
Over the past 22 years, more than €350 mill. have been invested in the LPA site. This new investment will eventually result in a threefold increase in the site’s inactivated vaccine production capacity.